2020年09月04日讯 / 生物谷 BIOON/ -- 礼来 （Eli Lilly）近日宣布，美国食品和药物管理局（FDA）已批准Trulicity（中文商品名：度易达，通用名：dulaglutide ...

对于 2 型糖尿病（T2D）血糖控制不佳的患者，提升 Dulaglutide（胰高血糖素样肽 - 1 受体激动剂，GLP - 1）剂量不如换用 Tirzepatide。研究发现，换用并加量 Tirzepatide 者 40 周后 21% 的人糖化血红蛋白 A1c（HbA1c）达标，且减重效果更好，安全性相似。此研究为 T2D 治疗提供新方向。

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

杜拉鲁肽 (Dulaglutide)通过抗炎抗氧化途径缓解阿霉素 (Doxorubicin)诱导的大鼠急性肾损伤 《Biologics: Targets and Therapy》：Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats 【字体： 大 中 小 】 时间：2025年07月14日 来源：Biologics: ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to ...

The Phase 3 study results of mazdutide versus dulaglutide reported at EASD were very successful. They showed comprehensive benefits of mazdutide in blood glucose control, weight loss and multiple ...

Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia Journal: Annals of Internal Medicine Published: 2024-08-27 DOI: 10.7326/m23-3220 Affiliations: 6 Authors: 6 See more ...